RevolKa Ltd., a venture-backed biotech company providing a cutting-edge artificial intelligence (AI)-driven protein engineering technology platform called aiProtein®, has raised $1.4 million in Series A extension funding.
This funding will advance RevolKa’s drug discovery programmes for rare diseases and support collaborative partnering efforts. This financing round was co-led by existing investors, D3 LLC (Tomoya Nagata, Managing Partner, CEO) and TOHOKU University Venture Partners Co. with participation from DEEPCORE Inc.
RevolKa’s core technology, aiProtein is a robust AI-driven protein engineering technology that creates exceptionally high-performance proteins. This technology platform has already produced many successful outcomes in collaboration with partner companies.
aiProtein® can simultaneously engineer multiple properties, offering a powerful and cost-effective solution for creating novel and highly functional proteins suitable for pharmaceutical and industrial applications.
